Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -300% Improvement Relative Risk Ventilation -300% ICU admission -300% Viral clearance 46% Viral clearance (b) 62% Discharge and WHO-OSC>2 -67% Favipiravir  Ivashchenko et al.  LATE TREATMENT  RCT Is late treatment with favipiravir beneficial for COVID-19? RCT 60 patients in Russia (April - May 2020) Improved viral clearance with favipiravir (p=0.028) c19early.org Ivashchenko et al., Clin. Infect. Dis., Aug 2020 Favors favipiravir Favors control

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Ivashchenko et al., Clin. Infect. Dis., doi:10.1093/cid/ciaa1176
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Interim results for a small RCT with 40 favipiravir and 20 control patients showing faster viral clearance with favipiravir. There is limited data in this report to evaluate the results. 75% of the control group received HCQ/CQ.
risk of death, 300.0% higher, RR 4.00, p = 0.55, treatment 2 of 40 (5.0%), control 0 of 20 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 29.
risk of mechanical ventilation, 300.0% higher, RR 4.00, p = 0.55, treatment 2 of 40 (5.0%), control 0 of 20 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 300.0% higher, RR 4.00, p = 0.55, treatment 2 of 40 (5.0%), control 0 of 20 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no viral clearance, 46.4% lower, RR 0.54, p = 0.03, treatment 15 of 40 (37.5%), control 14 of 20 (70.0%), NNT 3.1, mid-recovery day 5.
risk of no viral clearance, 62.5% lower, RR 0.37, p = 0.21, treatment 3 of 40 (7.5%), control 4 of 20 (20.0%), NNT 8.0, day 10.
risk of no discharge and WHO-OSC>2, 66.7% higher, RR 1.67, p = 0.51, treatment 10 of 40 (25.0%), control 3 of 20 (15.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ivashchenko et al., 9 Aug 2020, Randomized Controlled Trial, Russia, peer-reviewed, 21 authors, study period April 2020 - May 2020, average treatment delay 6.7 days.
This PaperFavipiravirAll
Abstract: Clinical Infectious Diseases BRIEF REPORT AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial Andrey A. Ivashchenko,1 Kirill A. Dmitriev,2 Natalia V. Vostokova,3 Valeria N. Azarova,3 Andrew A. Blinow,4 Alina N. Egorova,3 Ivan G. Gordeev,5 Alexey P. Ilin,6 Ruben N. Karapetian,7 Dmitry V. Kravchenko,6 Nikita V. Lomakin,8 Elena A. Merkulova,3 Natalia A. Papazova,9 Elena P. Pavlikova,10 Nikolay P. Savchuk,11 Elena N. Simakina,12 Tagir A. Sitdekov,2 Elena A. Smolyarchuk,13 Elena G. Tikhomolova,14 Elena V. Yakubova,4 and Alexandre V. Ivachtchenko11 ChemRar High-Tech Center, Khimki, Moscow region, Russian Federation, 2Russian Direct Investment Fund, Moscow, Russian Federation, 3IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation, 4Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation, 5City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation, 6Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation, 7Department of Biology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation, 8Central Clinical Hospital with Polyclinic, Moscow, Russian Federation, 9Department of Finished Dosage Forms, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation, 10Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation, 11Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation, 12Clinical Hospital No.1, Smolensk, Russian Federation, 13 First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation, and 14 Infectious clinical hospital No. 2, Nizhny Novgorod, Russian Federation 1 In May 2020 the Russian Ministry of Health granted fasttrack marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248. Keywords. AVIFAVIR; favipiravir; COVID-19; SARS-CoV-2.    The pandemic of the novel coronavirus infection (COVID-19) represents an unprecedented disaster for healthcare providers and economy worldwide. The urgent requirement for effective treatments has sparked an intense effort on the part of the pharmaceutical industry and shifted drug development to a new scale of commitment and collaboration. Received 26 June 2020; editorial decision 5 August 2020; accepted 6 August 2020; published online August 9, 2020. Correspondence: N. V. Vostokova, IPHARMA LLC, Moscow, Russian Federation (nv@ipharma.ru). Clinical Infectious Diseases®  2021;73(3):531–4 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com DOI: 10.1093/cid/ciaa1176 Repositioning of antiviral drugs that could be effective against SARS-CoV-2 is one of..
{ 'DOI': '10.1093/cid/ciaa1176', 'ISSN': ['1058-4838', '1537-6591'], 'URL': 'http://dx.doi.org/10.1093/cid/ciaa1176', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>In May 2020 the Russian Ministry of Health granted fast-track ' 'marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment ' 'of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled ' 'SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and ' 'well-tolerated.</jats:p>\n' ' <jats:p>Clinical Trials Registration. NCT04434248.</jats:p>', 'author': [ { 'affiliation': [ { 'name': 'ChemRar High-Tech Center, Khimki, Moscow region, Russian ' 'Federation'}], 'family': 'Ivashchenko', 'given': 'Andrey A', 'sequence': 'first'}, { 'affiliation': [{'name': 'Russian Direct Investment Fund, Moscow, Russian Federation'}], 'family': 'Dmitriev', 'given': 'Kirill A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian ' 'Federation'}], 'family': 'Vostokova', 'given': 'Natalia V', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian ' 'Federation'}], 'family': 'Azarova', 'given': 'Valeria N', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian ' 'Federation'}], 'family': 'Blinow', 'given': 'Andrew A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian ' 'Federation'}], 'family': 'Egorova', 'given': 'Alina N', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian ' 'Federation'}], 'family': 'Gordeev', 'given': 'Ivan G', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Chemistry and Technology, Chemical Diversity ' 'Research Institute, Khimki, Moscow region, Russian Federation'}], 'family': 'Ilin', 'given': 'Alexey P', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biology, Chemical Diversity Research Institute, ' 'Khimki, Moscow region, Russian Federation'}], 'family': 'Karapetian', 'given': 'Ruben N', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Chemistry and Technology, Chemical Diversity ' 'Research Institute, Khimki, Moscow region, Russian Federation'}], 'family': 'Kravchenko', 'given': 'Dmitry V', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Central Clinical Hospital with Polyclinic, Moscow, Russian ' 'Federation'}], 'family': 'Lomakin', 'given': 'Nikita V', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian ' 'Federation'}], 'family': 'Merkulova', 'given': 'Elena A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Finished Dosage Forms, Chemical Diversity Research ' 'Institute, Khimki, Moscow region, Russian Federation'}], 'family': 'Papazova', 'given': 'Natalia A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Moscow State University n.a. M. V. Lomonosov, Moscow, Russian ' 'Federation'}], 'family': 'Pavlikova', 'given': 'Elena P', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Chemical Diversity Research Institute, Khimki, Moscow region, ' 'Russian Federation'}], 'family': 'Savchuk', 'given': 'Nikolay P', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Clinical Hospital No.1, Smolensk, Russian Federation'}], 'family': 'Simakina', 'given': 'Elena N', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Russian Direct Investment Fund, Moscow, Russian Federation'}], 'family': 'Sitdekov', 'given': 'Tagir A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'First Moscow State Medical University n.a. I.M. Sechenov, ' 'Moscow, Russian Federation'}], 'family': 'Smolyarchuk', 'given': 'Elena A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Infectious clinical hospital No. 2, Nizhny Novgorod, Russian ' 'Federation'}], 'family': 'Tikhomolova', 'given': 'Elena G', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian ' 'Federation'}], 'family': 'Yakubova', 'given': 'Elena V', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Chemical Diversity Research Institute, Khimki, Moscow region, ' 'Russian Federation'}], 'family': 'Ivachtchenko', 'given': 'Alexandre V', 'sequence': 'additional'}], 'container-title': 'Clinical Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 8, 7]], 'date-time': '2020-08-07T03:41:52Z', 'timestamp': 1596771712000}, 'deposited': { 'date-parts': [[2021, 8, 2]], 'date-time': '2021-08-02T05:03:40Z', 'timestamp': 1627880620000}, 'funder': [ {'award': ['2020724139'], 'name': 'AVIFAVIR'}, {'award': ['2020724142', '2020724139'], 'name': 'Russian Direct Investment Fund'}, {'name': 'Trade of the Russian Federation and the Skolkovo Innovation Center'}], 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T15:54:09Z', 'timestamp': 1712591649926}, 'is-referenced-by-count': 161, 'issue': '3', 'issued': {'date-parts': [[2020, 8, 9]]}, 'journal-issue': { 'issue': '3', 'published-online': {'date-parts': [[2020, 8, 9]]}, 'published-print': {'date-parts': [[2021, 8, 2]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 8, 8]], 'date-time': '2020-08-08T00:00:00Z', 'timestamp': 1596844800000}}], 'link': [ { 'URL': 'http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1176/34459516/ciaa1176.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/cid/article-pdf/73/3/531/39508421/ciaa1176.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/cid/article-pdf/73/3/531/39508421/ciaa1176.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'page': '531-534', 'prefix': '10.1093', 'published': {'date-parts': [[2020, 8, 9]]}, 'published-online': {'date-parts': [[2020, 8, 9]]}, 'published-other': {'date-parts': [[2021, 8, 1]]}, 'published-print': {'date-parts': [[2021, 8, 2]]}, 'publisher': 'Oxford University Press (OUP)', 'reference': [ { 'DOI': '10.3389/fphar.2020.00791', 'article-title': 'Available evidence and ongoing clinical trials of remdesivir: could it ' 'be a promising therapeutic option for COVID-19?', 'author': 'Sisay', 'doi-asserted-by': 'crossref', 'first-page': '791', 'journal-title': 'Front Pharmacol', 'key': '2021080205021245000_CIT0001', 'volume': '11', 'year': '2020'}, { 'key': '2021080205021245000_CIT0002', 'volume-title': 'Avigan Tablet 200 mg. Report on the Deliberation Results. Evaluation and ' 'Licensing Division, Pharmaceutical and Food Safety Bureau. Ministry of ' 'Health, Labour and Welfare. March 4, 2014'}, { 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'author': 'Wang', 'doi-asserted-by': 'crossref', 'first-page': '269', 'journal-title': 'Cell Res', 'key': '2021080205021245000_CIT0003', 'volume': '30', 'year': '2020'}, { 'DOI': '10.1016/j.eng.2020.03.007', 'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label ' 'control study', 'author': 'Cai', 'doi-asserted-by': 'crossref', 'journal-title': 'Engineering', 'key': '2021080205021245000_CIT0004', 'year': '2020'}, { 'author': 'WHO R&D Blueprint COVID 19 Experimental Treatments.', 'key': '2021080205021245000_CIT0005', 'volume-title': 'COVID Classification of treatment types', 'year': '2020'}, { 'author': 'WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis.', 'key': '2021080205021245000_CIT0006'}, { 'author': 'Interim guidelines.', 'key': '2021080205021245000_CIT0007', 'volume-title': 'Prevention, diagnostics and treatment of a new coronavirus infection ' '(COVID-19), MOH of the Russian Federation'}, { 'DOI': '10.1002/sim.721', 'article-title': 'Sample size tables for exact single-stage phase II designs', 'author': 'A’Hern', 'doi-asserted-by': 'crossref', 'first-page': '859', 'journal-title': 'Stat Med', 'key': '2021080205021245000_CIT0008', 'volume': '20', 'year': '2001'}, { 'DOI': '10.1016/S2055-6640(20)30016-9', 'article-title': 'A review of the safety of favipiravir–a potential treatment in the ' 'COVID-19 pandemic?', 'author': 'Pilkington', 'doi-asserted-by': 'crossref', 'first-page': '45', 'journal-title': 'J Virus Erad', 'key': '2021080205021245000_CIT0009', 'volume': '6', 'year': '2020'}], 'reference-count': 9, 'references-count': 9, 'relation': { 'has-preprint': [ { 'asserted-by': 'object', 'id': '10.1101/2020.07.26.20154724', 'id-type': 'doi'}]}, 'resource': {'primary': {'URL': 'https://academic.oup.com/cid/article/73/3/531/5890024'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': 'AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim ' 'Results of a Phase II/III Multicenter Randomized Clinical Trial', 'type': 'journal-article', 'volume': '73'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit